BPC 157 Peptide Counteracted Venous Thrombosis and Its Complications in a Rat Model

Rats underwent inferior caval vein ligation up to the right ovarian vein to model Virchow's triad (vessel injury, stasis, thrombosis). BPC 157 was administered as either an early or delayed therapy regimen. Assessment included microcamera gross examination, microscopy, venography, bleeding time, blood pressure monitoring, ECG, thermography, plasma MDA and NO levels, tissue markers, and gene expression analysis via RT-PCR.

Venous thrombosis is a major clinical problem with limited treatment options beyond anticoagulants, which carry bleeding risks. This study suggests BPC 157 could address multiple aspects of venous disease simultaneously — thrombosis, vessel injury, hemodynamic disturbances, and oxidative stress — through a single peptide therapy, while also promoting the body's own compensatory mechanisms like collateral vessel formation.

BPC 157 research has consistently shown broad protective effects across various tissue injury models. This study extends those findings to venous thromboembolism, a condition that affects millions worldwide. The peptide's ability to simultaneously promote collateral vessel formation, normalize hemodynamics, and modulate oxidative stress markers suggests it acts through multiple complementary pathways rather than a single mechanism.

This is an animal study in rats, and results may not translate to humans. BPC 157 is not approved for human use by any regulatory agency. The abstract does not provide specific statistical comparisons or group sizes. The study comes from the Sikirić group, which produces the majority of BPC 157 research, and independent replication by other laboratories would strengthen the findings. Specific mechanisms of action remain incompletely characterized.